Volume 11; Issue 4

Molecular Cancer Therapeutics

Volume 11; Issue 4

1

A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma

Dutton-Regester, K., Irwin, D., Hunt, P., Aoude, L. G., Tembe, V., Pupo, G. M., Lanagan, C., Carter, C. D., O'Connor, L., O'Rourke, M.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 492 KB

english, 2012

2

Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide

Hu, C., Lancaster, C. S., Zuo, Z., Hu, S., Chen, Z., Rubnitz, J. E., Baker, S. D., Sparreboom, A.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 670 KB

english, 2012

3

CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy

Siddiqui-Jain, A., Bliesath, J., Macalino, D., Omori, M., Huser, N., Streiner, N., Ho, C. B., Anderes, K., Proffitt, C., O'Brien, S. E.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 931 KB

english, 2012

4

A Novel Monoclonal Antibody to Fibroblast Growth Factor 2 Effectively Inhibits Growth of Hepatocellular Carcinoma Xenografts

Wang, L., Park, H., Chhim, S., Ding, Y., Jiang, W., Queen, C., Kim, K. J.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 806 KB

english, 2012

5

Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy

Vosjan, M. J. W. D., Vercammen, J., Kolkman, J. A., Stigter-van Walsum, M., Revets, H., van Dongen, G. A. M. S.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 766 KB

english, 2012

6

Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma

McMillin, D. W., Jacobs, H. M., Delmore, J. E., Buon, L., Hunter, Z. R., Monrose, V., Yu, J., Smith, P. G., Richardson, P. G., Anderson, K. C., Treon, S. P., Kung, A. L., Mitsiades, C. S.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 757 KB

english, 2012

7

Honokiol in Combination with Radiation Targets Notch Signaling to Inhibit Colon Cancer Stem Cells

Ponnurangam, S., Mammen, J. M. V., Ramalingam, S., He, Z., Zhang, Y., Umar, S., Subramaniam, D., Anant, S.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 2.55 MB

english, 2012

8

Serine-305 Phosphorylation Modulates Estrogen Receptor Alpha Binding to a Coregulator Peptide Array, with Potential Application in Predicting Responses to Tamoxifen

Houtman, R., de Leeuw, R., Rondaij, M., Melchers, D., Verwoerd, D., Ruijtenbeek, R., Martens, J. W. M., Neefjes, J., Michalides, R.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 1.38 MB

english, 2012

9

Cigarette Smoke Induces Aberrant EGF Receptor Activation That Mediates Lung Cancer Development and Resistance to Tyrosine Kinase Inhibitors

Filosto, S., Becker, C. R., Goldkorn, T.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 1.46 MB

english, 2012

10

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

Zou, H. Y., Li, Q., Lee, J. H., Arango, M. E., Burgess, K., Qiu, M., Engstrom, L. D., Yamazaki, S., Parker, M., Timofeevski, S., Cui, J. J., McTigue, M., Los, G., Bender, S. L., Smeal, T., Christensen

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 1.10 MB

english, 2012

11

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., Ricketts, S.-A., Cross, D., Cosulich, S., Chresta, C. C., Page, K., Yates, J., Lane,

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 871 KB

english, 2012

12

Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells

Rao, R., Balusu, R., Fiskus, W., Mudunuru, U., Venkannagari, S., Chauhan, L., Smith, J. E., Hembruff, S. L., Ha, K., Atadja, P., Bhalla, K. N.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 1004 KB

english, 2012

13

NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

Valsasina, B., Beria, I., Alli, C., Alzani, R., Avanzi, N., Ballinari, D., Cappella, P., Caruso, M., Casolaro, A., Ciavolella, A., Cucchi, U., De Ponti, A., Felder, E., Fiorentini, F., Galvani, A., Gi

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 802 KB

english, 2012

14

CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity

James, J., Ruggeri, B., Armstrong, R. C., Rowbottom, M. W., Jones-Bolin, S., Gunawardane, R. N., Dobrzanski, P., Gardner, M. F., Zhao, H., Cramer, M. D., Hunter, K., Nepomuceno, R. R., Cheng, M., Gitn

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 616 KB

english, 2012

15

SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 1.99 MB

english, 2012

16

MiR-196a Is Upregulated in Gastric Cancer and Promotes Cell Proliferation by Downregulating p27kip1

Sun, M., Liu, X.-h., Li, J.-h., Yang, J.-s., Zhang, E.-b., Yin, D.-d., Liu, Z.-l., Zhou, J., Ding, Y., Li, S.-q., Wang, Z.-x., Cao, X.-f., De, W.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 1.84 MB

english, 2012

17

Prognostic Role of KiSS-1 and Possibility of Therapeutic Modality of Metastin, the Final Peptide of the KiSS-1 Gene, in Urothelial Carcinoma

Takeda, T., Kikuchi, E., Mikami, S., Suzuki, E., Matsumoto, K., Miyajima, A., Okada, Y., Oya, M.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 960 KB

english, 2012

18

Navitoclax (ABT-263) Reduces Bcl-xL-Mediated Chemoresistance in Ovarian Cancer Models

Wong, M., Tan, N., Zha, J., Peale, F. V., Yue, P., Fairbrother, W. J., Belmont, L. D.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 1.61 MB

english, 2012

19

HER2 As Therapeutic Target for Overcoming ATP-Binding Cassette Transporter-Mediated Chemoresistance in Small Cell Lung Cancer

Minami, T., Kijima, T., Otani, Y., Kohmo, S., Takahashi, R., Nagatomo, I., Hirata, H., Suzuki, M., Inoue, K., Takeda, Y., Kida, H., Tachibana, I., Kumanogoh, A.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 1.33 MB

english, 2012

20

Autophagy Inhibition Synergistically Enhances Anticancer Efficacy of RAMBA, VN/12-1 in SKBR-3 Cells, and Tumor Xenografts

Godbole, A. M., Purushottamachar, P., Martin, M. S., Daskalakis, C., Njar, V. C. O.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 1.34 MB

english, 2012

21

The Thymidine Phosphorylase Inhibitor 5'-O-Tritylinosine (KIN59) Is an Antiangiogenic Multitarget Fibroblast Growth Factor-2 Antagonist

Liekens, S., Bronckaers, A., Belleri, M., Bugatti, A., Sienaert, R., Ribatti, D., Nico, B., Gigante, A., Casanova, E., Opdenakker, G., Perez-Perez, M.-J., Balzarini, J., Presta, M.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 2.02 MB

english, 2012

22

Therapeutic Efficacy of CEP-33779, a Novel Selective JAK2 Inhibitor, in a Mouse Model of Colitis-Induced Colorectal Cancer

Seavey, M. M., Lu, L. D., Stump, K. L., Wallace, N. H., Hockeimer, W., O'Kane, T. M., Ruggeri, B. A., Dobrzanski, P.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 1.09 MB

english, 2012

23

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

Greger, J. G., Eastman, S. D., Zhang, V., Bleam, M. R., Hughes, A. M., Smitheman, K. N., Dickerson, S. H., Laquerre, S. G., Liu, L., Gilmer, T. M.

Journal:

Molecular Cancer Therapeutics

Year:

2012

Language:

english

File:

PDF, 2.06 MB

english, 2012